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RESEARCH LETTER
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Clinical characteristics of
heart failure patients
undergoing atrial fibrillation
ablation today in Europe.
Data from the atrial
fibrillation registries of the
European Society of
Cardiology and the European
Heart Rhythm Association
Over the past three decades, catheter abla-
tion of atrial fibrillation (AF) has evolved from
an investigational procedure to its current
role as a standard treatment option. Current
guidelines recommend catheter ablation
for symptomatic AF patients, preferring
non-pharmacological therapy or resistant
to antiarrhythmic drugs.1 However, which
patients with AF and heart failure (HF) are
actually referred for AF ablation in clinical
practice today is still unclear, and the indi-
cation criteria are likely to be reconsidered
by cardiologists in the light of the recent
published literature.
A recent non individual-based meta-
analysis of six small randomized controlled
trials (RCTs) including 775 HF patients, most
with persistent AF, mean age 55–64 years,
reduced left ventricular ejection fraction (EF)
(mean 28.3%), and a mean follow-up longer
than 12months, showed an improvement
of both EF and patient functional capacity
associated with a significant reduction of
both readmission and death rates.2 Since
then, results of two larger RCTs have been
reported. The CASTLE-AF trial, including
339 HF patients (EF ≤ 35%) out of 3013
patients assessed for enrolment over a
period of 8 years, showed a lower rate of the
combined endpoint of death and hospitaliza-
tion for HF with AF ablation than medical
therapy (hazard ratio 0.62, 95% confidence
interval 0.43–0.87).3 The CABANA trial
comparing AF ablation vs. antiarrhythmic
pharmacological therapy included 2204 AF
patients, with only 15% having a history
of congestive HF (the results have been
reported but are yet unpublished).4 Based
on the original intention-to-treat trial design,
the results were neutral, however, in the
on-treatment analysis, due to an (expected)
shift of approximately one third of patients
randomized to drug treatment to the ablation
arm, with a significant benefit on the primary
endpoint in the ablation group (7% vs. 10.9%;
hazard ratio 0.67, 95% confidence interval
0.50–0.89).
An attempt to understand which HF
patients cardiologists actually do select
as candidates for AF ablation is therefore
worthwhile, and prospective registries on AF
recently conducted by the European Soci-
ety of Cardiology (ESC) and the European
Heart Rhythm Association may offer such
an opportunity. This applies in particular
to two published registries, the Atrial Fib-
rillation Ablation (AFA) Registry aimed at
providing an observational picture of con-
temporary real-world AF ablation strategy
and its outcome5 and the Atrial Fibrillation
General Pilot (AFG) Registry6 collected
in Europe within approximately the same
time frame, by partly overlapping centre
networks, and conducted by the same ESC
management team. In the AFA registry,
most patients underwent a first ablation
procedure, while 19% had a redo procedure.
In the AFG registry, 7.6% of patients had
undergone an AF ablation procedure before
enrolment in the registry, while ablation was
performed or planned at admission in 6.8%
of patients. We specifically focused on the
HF patients enrolled in both studies: 537
(14.9%) in AFA and 1382 (46.5%) in AFG,
respectively.
The clinical characteristics of these HF
cohorts are summarized in Table 1. AFA
patients were a decade younger, had less
prevalent cardiovascular risk factors (e.g.
diabetes, hypercholesterolaemia, smok-
ing habit) than AFG patients, and a lower
risk of both stroke (CHA2DS2-VASc) and
bleeding (HAS-BLED). While there were
no differences in baseline blood pressure
and gender ratio between the two cohorts,
mean heart rate was faster in the general
AF cohort than in ablated patients. Under-
lying or concomitant clinical disorders such
as coronary and peripheral artery disease,
valvular heart disease, previous transient
ischaemic attack, chronic kidney and liver
disease, and chronic obstructive pulmonary
disease were less common in ablated patients
than in the general AF population. As
expected, the rate of paroxysmal AF was
two-fold higher in the AFA HF patients, which
were more symptomatic than the AFG HF
patients.
AFA patients had smaller left atrial size
and higher EF at echocardiographic imaging.
Most AFA patients (77%) had a preserved EF
(≥ 50%, HFpEF), while those with mid-range
EF (40–49%, HFmrEF) or reduced EF (< 40%,
HFrEF) were a relatively small minority (15%
and 8%, respectively). The relative proportion
of the EF phenotypes among AFG patients
was more balanced (HFpEF 46%, HFmrEF
21%, HFrEF 33%). The clinical profile of each
EF subtype of ablated patients was more
favourable than that of the corresponding
HF patients in the AFG registry (data not
reported).
The few data reported above are descrip-
tive, and the analysis only underscores a
few major differences between the two
AF cohorts. In fact, they are different by
definition. In both groups, the setting is the
same – the cardiology department – but
the AFA patients were selected for an atrial
ablation, whereas the AFG patients were
seeking for clinical care. The differences
between them outline the interventional
niche reserved to co-morbid HF-AF patients
in Europe today, which probably reflects
a certain clinical cautiousness. The choice
for intervention appears more focused on
relieving AF-related symptoms than on an
attempt to influence the clinical course of HF.
Whether or not the most recent randomized
trials3,4 may prompt a more extensive use
of AF ablation in HF patients is open to
debate.7,8 Besides other considerations, a
potential limitation of the RCTs conducted
so far is the uncertain representativeness
of the patients enrolled. Organizational
and methodological difficulties encountered
in enrolling randomized patients and the
consequent methodological adjustments
inevitably impact on the representativeness
of the study population. For instance, in our
open AFA cohort, only 42 patients with EF
≤ 35% were included, and only nine of these
had a cardioverter-defibrillator implanted
(both entry criteria in the CASTLE-AF
trial).
Conflict of interest: none declared.
© 2019 The Authors
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2 Research letter
Table 1 Clinical characteristics of heart failure patients in the Atrial Fibrillation Ablation Long-Term (AFA) Registry
vs Atrial Fibrillation General Pilot Registry
HF AFA (n= 537) HF AFG (n= 1382) P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Demographics
Age, years [mean (SD)] 59.9 (8.9) 70.7 (10.8) <0.001
Men, n (%) 339/537 (63.1) 816/1382 (59.0) 0.101
Body mass index > 30 kg/m2, n (%) 215/515 (41.7) 422/1350 (31.3) <0.001
Systolic blood pressure, mmHg [mean (SD)]/n 131.0 (17.3)/529 133.1 (23.4)/1382 0.203
Diastolic blood pressure, mmHg [mean (SD)]/n 81.1 (10.3)/529 79.3 (14.2)/1382 <0.001
Heart rate, b.p.m. [mean (SD)]/n 79.3 (24.7)/496 91.3 (28.8)/1375 <0.001
Cardiovascular risk factors, n (%)
Diabetes mellitus 78/536 (14.6) 374/1373 (27.2) <0.001
Hypertension 393/536 (73.3) 1034/1375 (75.2) 0.396
Smoking (present or former) 129/518 (24.9) 557/1337 (41.7) <0.001
Hypercholesterolaemia 231/525 (44.0) 754/1352 (55.8) <0.001
Ischaemic thromboembolic events 44/534 (8.2) 220/1362 (16.2) <0.001
CHA2DS2-VASc score, n (%) <0.001
1 67/532 (12.6) 54/1382 (3.9)
2 176/532 (33.1) 168/1382 (12.2)
3 159/532 (29.9) 250/1382 (18.1)
4 75/532 (14.1) 339/1382 (24.5)
≥ 5 54/532 (10.2) 571/1382 (41.3)
HAS-BLED score, n (%)
0 321/523 (61.4) 187/1382 (13.5) <0.001
1 162/523 (31.0) 470/1382 (34.0)
≥ 2 40/523 (7.6) 725/1382 (52.5) <0.001
Type of AF <0.001
Paroxysmal 302/537 (56.2) 319/1379 (23.1)
Persistent 172/537 (32.0) 467/1379 (33.9)
Long-standing persistent 63/537 (11.7) 120/1379 (8.7)
Permanent – 473/1379 (34.3)
AF underlying disorder, n (%)
Coronary artery disease 190/520 (36.5) 597/1200 (49.8) <0.001
Dilated cardiomyopathy 47/536 (8.8) 305/1359 (22.4) <0.001
Hypertensive cardiomyopathy 166 534 (31.1) 340/1365 (24.9) 0.006
Hypertrophic cardiomyopathy 13/537 (2.4) 80/1364 (5.9) 0.002
Valvular heart disease 104/534 (19.5) 1024/1350 (75.9) <0.001
Hyperthyroidism 25/530 (4.7) 45/1303 (3.5) 0.201
Other cardiac disease 48/535 (9.0) 121/1295 (9.3) 0.803
Concomitant clinical conditions, n (%)
Previous TIA 9/535 (1.7) 54/1354 (4.0) 0.012
Previous stroke 33/535 (6.2) 113/1364 (8.3) 0.119
Peripheral vascular disease 28/527 (5.3) 225/1347 (16.7) <0.001
Chronic kidney disease 16/527 (3.0) 299/1373 (21.8) <0.001
Liver disease 11/528 (2.1) 106/1375 (7.7) <0.001
COPD 18/527 (3.4) 211/1364 (15.5) <0.001
Haemorrhagic events 5/530 (0.9) 93/1361 (6.8) <0.001
Malignancy 13/532 (2.4) 72/1324 (5.4) 0.005
EHRA score, n (%)
1 3/536 (0.6) 514/1382 (37.2) <0.001
2 229/536 (42.7) 339/1382 (24.5)
3 257/536 (47.9) 425/1382 (30.8)
4 47/536 (8.8) 104/1382 (7.5)
© 2019 The Authors
European Journal of Heart Failure © 2019 European Society of Cardiology
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Research letter 3
Table 1 Continued
HF AFA(n= 537) HF AFG(n= 1382) P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Associated symptoms, n (%)
Palpitations 425/536 (79.3) 636/1382 (46.0) <0.001
Fatigue 311/536 (58.0) 491/1382 (35.5) <0.001
Dyspnoea 339/536 (63.2) 945/1382 (68.4) 0.082
Weakness 289/536 (53.9) 363/1382 (26.3) <0.001
Dizziness 111/536 (20.7) 240/1382 (17.4) 0.089
Chest pain 166/536 (31.0) 220/1382 (15.9) <0.001
Echocardiographic data
LVEF, n (%) 488 (90.9) 1045 (75.6)
LVEF, mean % (SD) 55.9 (11.5) 44 6 (13.9) <0.001
Left atrial diameter, n (%) 455 (84.7) 1202 (87.0)
Left atrial diameter, mean mm (SD) 45.1 (6.9) 46 9 (8.9) 0.011
AF, atrial fibrillation; AFA, Atrial Fibrillation Ablation Long-Term Registry; AFG, Atrial Fibrillation General Pilot Registry; COPD, chronic obstructive pulmonary disease; HF,
heart failure; ICD, implantable cardioverter-defibrillator; CRT, cardiac resynchronization therapy; EHRA, European Heart Rhythm Association; LVEF, left ventricular ejection
fraction; PM, pacemaker; SD, standard deviation; TIA, transient ischaemic attack.
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